2025 International Congress Archives

P2P Therapeutics Platform Trial in Stage 2B Neuronal Alpha-Synuclein Disease: Study Design and Statistical Considerations

T. Simuni, C. Coffey, A. Siderowf, C. Tanner, M. Brumm, S. Chowdhury, T. Sherer, C. Kopil, K. Kieburtz, C. Allen-Savietta, B. Wendelberger, A. Crawford, T. Tropea, K. Fabrizio, H. Whalen, K. Marek (Chicago, USA)
PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment

T. Nikolcheva, G. Pagano, J. Anzures-Cabrera, T. Simuni, K. Marek, N. Pavese, K. Seppi, F. Stocchi, R. Postuma, N. Pross, A. Monnet, G. Respondek, L. Rutten-Jacobs, V. Schlegel, L. Boak, G. Kerchner, P. Brundin, H. Svoboda, A. Bonni (Basel, Switzerland)
Paeoniflorin Combined with Neural Stem Cell Transplantation for Parkinson’s Disease: Synergistic Effects of Cell Therapy and Inflammation Regulation

SJ. Peng, LP. Wang, YJ. Ou, RE. Liu (Beijing, China)
Pain Assessment in Cervical Dystonia: Insights from the PIDS and Dystonia-PCS Scales

F. Rolim, D. Monteiro, P. Santos, A. Lima Verde, D. Portela, M. Cordellini, C. Listik, F. Carvalho (Fortaleza, Brazil)
Painful Legs Moving Toes Syndrome in Rural Western India: Etiological Spectrum and Outcomes in 24 Cases

S. Desai, D. Desai (Anand, India)
Pallidotomy Reborn? Revisiting GPi Lesions in the Era of Neuro modulation for Parkinson’s Disease

P. Brainer, J. Brainer, A. Brainer, M. Magela, M. Cavalcanti, A. Oliveira, P. Brainer (recife, Brazil)
Paradoxical Association of Kinetics of α-Synuclein Seed Amplification 24-hrs Assay and Clinico-Pathological Markers of Parkinson’s disease

SM. Fereshtehnejad, Y. Zeighami, C. Marras (TORONTO, Canada)
Parameterization of Intraoperative Human Microelectrode Recordings: Linking Action Potential Morphology to Brain Anatomy

M. Baker, B. Klassen, M. Jensen, G. Ojeda Valencia, H. Heydari, N. Ince, K. Müller, K. Miller (Rochester, USA)
Parkinson disease subtype stability and eventual convergence

H. Lessov-Schlaggar, A. Eid, T. Cash, E. Foster, B. Maiti, H. Hwang, R. Perrin, P. Kotzbauer, J. Perlmutter, M. Campbell (Saint Louis, USA)
Parkinson`s disease future prediction

V. Raju, A. Dabbeta (Hyderabad, India)
Parkinson’s Disease and Cancer: A Meta-Analysis of Prevalence, Risk, and Specific Associations with Brain and Skin Cancers

H. Khelifa, A. R. Al-Ihribat, H. Smeda, A. Hendawy, A. Abunamoos (Oran, Algeria)
Parkinson’s Disease and Movement Disorders Mortality in Tunisia: Insights from the National Information System on Causes-of-Death (2020-2021)

M. Zribi, N. Zoghlami, S. Ben Maryem, M. Bennour, H. Aounallah-Skhiri (Tunis, Tunisia)
Parkinson’s Disease Diagnosed in a Patient with Anti-Musk Positive Myasthenia Gravis: Coincidence? – Case Report and Literature Review

J. Sánchez León, T. Luise Denicol, C. Matté Dagostini, R. de Castro, A. Hilbig, A. Hoppe, C. Mello Rieder (Porto Alegre, Brazil)
Parkinson’s Disease Epidemiology and Treatment Characteristics in Australia

M. Lubomski, A. Evans, R. Mackinnon, R. Rossiter, M. Falster, M. Kouhkamari, T. Suresh, A. Mikolaizak, J. Waern (St Leonards, Australia)
Parkinson’s disease GWAS-linked SNCA carriers show slower non-motor and cognitive progression

DX. Deng, LT. Tan, TEK. Tan (singapore, Singapore)
Parkinson’s Disease: Increased Presence of Neuropsychiatric Symptoms and Non-Motor Issues Drive Higher Medication Use and Costs

S. Horn, E. Vaou, A. Parab, S. Wang, X. Pan, C. Yan, M. Shah, J. Jimenez-Shahed (San Antonio, USA)
Parkinson’s Disease (PD) and Type II Diabetes (T2DM): Risk and Progression

S. Goldman, F. Weaver, L. Cao, B. Gonzalez, S. Jugnundan, K. Stroupe, K. Colletta, E. Brown, C. Tanner (San Francisco, USA)
Parkinson’s disease (PD) associated with the E46K mutation in the SNCA gene, twenty years after

B. Tijero Merino, MA. Acera Gil, I. Gabilondo, T. Fernandez Valle, M. Ruiz Lopez, R. Sanchez Pernaute, A. Murueta-Goyena, I. Diez, C. Juanes, R. Del Pino, N. Ayo-Mentxakatorre, JC. Gomez-Esteban (Barakaldo, Spain)
Parkinson’s Disease and Type 2 Diabetes Severity: a Case-control Biomarker Study

B. Huxford, A. Zirra, E. Camboe, K. Dey, D. Gallagher, C. Budu, C. Simonet, T. Boyle, R. Dobson, A. Noyce (London, United Kingdom)
Parkinson’s Disease Dogs to assist Gait Impairment: A Pilot study of Patient Experience and Outcomes

A. Gallagher, C. O'Keeffe, J. Inocentes, J. Liegey, J. Dowler, C. Fearon, T. Lynch (Dublin, Ireland)
Parkinson’s Disease Health Policy in 7 African Countries: Results of a Transforming Parkinson’s Care in Africa (TraPCAf) Review

R. Morton, A. Rogers, H. Francis, M. Cham, J. Lumsdon, C. Dotchin, E. Hamid, A. Akpalu, S. Gugssa, B. Mushengezi, O. Ojo, N. Okubadejo, D. Sokhi, R. Walker, N. Fothergill-Misbah (Newcastle upon Tyne, United Kingdom)
Parkinson’s disease motor phenotypes delineated by pallidal and subthalamic neurophysiology and machine learning

V. Lavu, P. Coutinho, J. Hilliard, K. Foote, C. de Hemptinne, J. Wong, K. Johnson (Gainesville, USA)
Parkinson’s disease overlapping with other neurodegeneration-case series with neuropathological description.

L. Milanowski, A. Salinska, A. Acewicz, M. Grzegorczyk, S. Tarka, S. Szlufik, T. Wierzba-Bobrowicz, D. Koziorowski (Warsaw, Poland)
Parkinson’s disease Symptoms Mitigated by Photobiomodulation: The Potential of the Tryptophan Kynurenine Ratio as a Marker for Responsiveness to Therapy.

A. Liebert, B. Bicknell (Wahroonga, Australia)
Parkinson’s Exercise Guidelines: From Outdated to Updated

M. Rafferty, L. Hoffman, L. Krasucki, D. Corcos (Chicago, USA)
Parkinson’s Progression Markers Initiative (PPMI): A Biomarker Engine for Therapeutic Development for PD and Related Synucleinopathies

B. Mcmahon, A. Videnovic, A. Siderowf, B. Mollenhauer, C. Tanner, C. Coffey, C. Stanley, D. Weintraub, D. Galasko, E. Flagg, E. Brown, K. Merchant, K. Kieburtz, K. Poston, K. Marek, K. Fabrizio, L. Chahine, M. Kuhl, M. Frasier, R. Dobkin, R. Alcalay, S. Chowdury, T. Simuni, T. Foroud, T. Sherer, T. Tropea (Boston, USA)
Parkinsonism after Post-Anoxic Brain Injury

B. Petko, S. Factor, R. Tripathi (Atlanta, USA)
Parkinsonism Due to Delayed Neurotoxicity of CAR-T Therapy

M. Murzello, A. Pena (Jacksonville, USA)
Parkinsonism following Chronic Disulfiram Overdose

S. Ray, V. Kamath, B. Bairy (Bangalore, India)
Parkinsonism in a case of Gerstmann Sträussler Scheinker disease

S. Poveda, O. Bernal-Pacheco, L. Lancheros, J. Montealegre (Bogotá, Colombia)
Parkinsonism in KMT5B-related Disorders: Expanding the Spectrum.

P. Rábano-Suárez, A. Sánchez-Ferro, A. Arteche-López, JF. Quesada, R. Pérez, M. Morales, L. Jiménez Díez-Canseco, A. Galiana, A. Méndez-Guerrero (Madrid, Spain)
Parkinsonism in Uzbekistan: Clinical and Demographic Insights from 2024

Y. Nishonova, B. Mukhammedaminov, L. Kenjaeva, N. Aripova (Tashkent, Uzbekistan)
PARKinSOUND 2.0: The Impact of Orchestra Participation on Patients with Parkinson’s Disease

S. Lopes, A. Ferreira, S. Gomes, C. Morgado, L. Costa, A. Goios, J. Ferreira, M. Rodrigues (Braga, Portugal)
Paroxysmal Nonkinesigenic Dyskinesia in GLUT1 Deficiency Syndrome: A Rare Manifestation

A. Medhus, E. Krause (Austin, USA)
Paroxysmal Post-Traumatic Dystonia in Patients with Whiplash and Mild Traumatic Brain Injuries

H. Peltonen, R. Ortiz, J. Honkaniemi (Tampere, Finland)
Pathogenic TBK1 Mutation Associated with Multiple System Atrophy-Like Phenotype

S. Barton, C. Siskind, H. Zahed (Palo Alto, USA)
Pathology Meets Clinical Practice: Unveiling the Pathological Evidence of Clinical Signs in Multiple System Atrophy

E. Zhunusova, P. Panyakaew, C. Shambetova, R. Bhidayasiri (Bishkek, Kyrgyzstan)
Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis

N. Smith, B. Amlani (Reading, United Kingdom)
Patient engagement in Parkinson’s research: Exploring stakeholder perspectives

J. Bek, N. Simonian, C. Rattan, A. Asis (Dublin, Ireland)
Patient Experience and Satisfaction With Once-Daily Deutetrabenazine Extended-Release Tablets for Treatment of Huntington Disease-Related Chorea

B. Bulica, M. Konings, S. Thompson, A. Yang, S. Kotak, P. Gandhi (Detroit, USA)
Patient Perspectives on the Therapeutic Effects of Botulinum Toxin in Cervical Dystonia

M. Relja, D. Dressler, F. Morgante, V. Trjulja (Zagreb, Croatia)
Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics

K. Luk, B. Li, S. Song, N. Newman (Cambridge, USA)
Patient-Reported Satisfaction and Usability of a Virtual Home-Based Program for Fall Prevention in Parkinson’s Disease

S. Dharmadhikari, V. Palakuzhy, Y. Kianirad, M. Afshari (Chicago, USA)
Patient-reported Symptoms and their Impact in Hereditary Spastic Paraplegia and Spastic Ataxias

M. Ademi, C. Dubec-Fleury, J. Morales Saute, J. Greenfield, R. Wallis, C. Gobeil, L. Renna Linton, A. Nadke, R. Horvath, F. Santorelli, B. de Warrenburg, M. Synofzik, S. Du Montcel, P. Consortium, R. Schüle (Heidelberg, Germany)
Patient-specific Vascularized Midbrain Assembloids with Microglia show Altered Neuroinflammatory Phenotypes in Parkinson’s Disease

A-S. Zimmermann, S. Sabate-Soler, A. Zagare, J. Schwamborn (Belvaux, Luxembourg)
Patients’ Perspective on Screening for Non-Motor Symptoms in Parkinson’s Disease, A QI Project

C. Flavin, G. Lamotte, P. Moretti (Salt Lake City, USA)
Patterns and Predictors of Cholinesterase Inhibitor Use in Dementia with Lewy Bodies

R. Heo, A. Negida, K. Wyman-Chick, J. Bateman, F. Rodriguez-Porcel, B. Berman, N. Mukhopadhyay, M. Barrett (Richmond, USA)
People With Parkinson’s Disease and Care Partners Experience Costly Work Productivity Loss

I. Malaty, N. Boame, A. Parab, S. Wang, M. Shah, C. Yan, J. Jimenez-Shahed (Gainesville, USA)
Perceived Versus Actual Performance During Dual-Task Walking: Insights from Parkinson’s Disease

H. Johansson, B. Leavy (Stockholm, Sweden)
Perception of the Deep Brain Stimulation Therapeutic Window: An Anatomically Informed Survey

L. Gozman, J. Wong, L. Fanty (Gainesville, USA)
Perceptual Decision Making in Cervical Dystonia: Development of a a Novel Integrated Neurobehavioural-Neurophysiological Method.

O. Killian, A. Gill, K. Miyauchi, S. Rafee, S. O'Riordan, L. Williams, C. Fearon, R. Reilly (Dublin, Ireland)
Performance Validity Test Failure Base Rates Among Presurgical Movement Disorder Patients

J. Numerick, A. Karstens, D. Gonzalez, D. Ulrich (Chicago, USA)
Perinatal Dioxin Exposure and Dopaminergic Vulnerability in the Development of Motor Dysfunction Sequelae

N. Choudhury, S. Shugar, B. Carr (Gainesville, USA)
Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease

N. Vijiaratnam, C. Girges, J. Dickson, C. Caroll, M. Silverdale, M. Hu, G. Duncan, K. Chaudhuri, S. Gandhi, D. Athauda, Y. Li, N. Greig, K. Chowdhury, T. Foltynie (London, United Kingdom)
Peripheral neuropathy in Autosomal Recessive Spinocerebellar Ataxia due to ANO10 mutation – Expanding the phenotypic spectrum

A. Vijayaraghavan (Thiruvananthapuram, India)
Peripheral unspecific inflammatory parameters – not always useful in differential diagnosis of parkinsonian syndromes.

N. Madetko-Alster, P. Alster (Warsaw, Poland)
Personalised Success: Evaluating Hemifacial Spasm Treatment with Goal Attainment Scale

S. Maytharakcheep, O. Phokaewvarangkul, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)
Personality Profiles in Patients with Functional Motor Disorders

V. Nistico', S. Cuoco, R. Bisogno, R. Tedesco, C. Civilotti, O. Gambini, P. Barone, B. Demartini, R. Erro (Salerno, Italy)
Personality Traits and Neuropsychiatric Assessment in De Novo, Clinically Established Body-First and Brain-First Parkinson’s Disease

P. Antenucci, M. Sensi, V. Resta, L. Spanedda, D. Zecchinato, G. Linzalone, A. Gozzi, L. Zerbinati (Ferrara, Italy)
Pesticide Exposure and Parkinson’s Disease Motor Subtype

D. Thordarson, J. Bronstein, A. Keener, B. Ritz, K. Paul (Los Angeles, USA)
PET and Clinical Evidence for Neuroprotective Effects of KM-819 on MSA

C. Lee, C. Barlow, E. Kim, D. Kim, D. Doudet, J. Ko, M. Goh (Seongnam-si, Gyeonggi-do, Republic of Korea)
Pharmacokinetic Analysis of Subcutaneous Levodopa/Carbidopa Delivery With ND0612

L. Adar, N. Vostokova, I. Hadari Naor, G. Smania, M. Ibrahim, J. Pereira, I. Perlstein, M. Karlsson (Rehovot, Israel)
Pharmacological PGC-1α Activation Mitigates Dopaminergic Degeneration in Parkinson’s Disease Via Regulating Mitochondrial Homeostasis

J. Kaur, S. Naqvi (Lucknow, India)
Phase 1 and 1b Pharmacodynamic Data Support Central Modulation of Lysosomal Pathways With BIIB122/DNL151, a LRRK2 Kinase Inhibitor: Insights for the LUMA Trial

K. Fraser, A. Lang, L. Kalia, R. Hauser, J. Greenamyre, Y. Moroishi, J. Kluss, B. Hersh, K. Ferber, R. Maciuca, C. Paián-Ruiz, R. Llorens-Arenas, D. Jennings, S. Huntswork-Rodriguez, D. Graham (Tampa, USA)
Phase I randomized, double-blind study to evaluate feasibility, safety, and clinical responses of implanting autologous peripheral nerve tissue into the nucleus basalis of Meynert or substantia nigra for non-motor or motor symptoms in patients with Parkinson’s disease undergoing DBS surgery (STAR) Trial

J. Quintero, J. Slevin, J. Hixson, G. Gerhardt, C. van Horne (Lexington, USA)
Phenotypic Overlap of CACNA1A-Related Disorders

M. Rochman, A. Dessy (Phialdelphia, USA)
Phenotypic spectrum and response to deep brain stimulation (DBS) in patients with dystonia due to variants in the KMT2B gene: A description of six Chilean cases

D. Munoz Chesta, M. Troncoso, C. Foradori, P. Salles, D. Aguirre (Santiago, Chile)
Phenotypic Spectrum In Children And Adolescents With Glucose Transporter 1 Deficiency A Multicentric Retrospective Study

S. Yoganathan, C. Pefaur, V. Gowda, V. Cornejo, V. Quiroz, P. Jain, S. Sharma, L. Guilder, G. Costain, I. Tein, C. Gorodetksy (Toronto, Canada)
Phenotypic Spectrum of Movement Disorders in TBC1D24 Gene Variants: A Case Series

K. Chesky, M. Parnes, M. Hull (Houston, USA)
Phenotypic Variability Across Four Generations in a Family with CACNA1A Mutation

R. Usman, M. Moreno Escobar (Morgantown, USA)
Phenotypic, Genotypic, Imaging and Neuropsychological Profile of Friedreich Ataxia

R. Devaraj, R. Yadav, J. Saini, S. Hegde, M. Faruq, P. Pal (Bengaluru, India)
Phenotypical Study of Progressive Myoclonic Epilepsy in Eastern Algeria

SM. Behloul, Y. Mecheri, A. Boulefkhad (Constantine, Algeria)
PHIT-Brain Study Protocol: Adaptation and Evaluation of a Multifaceted Brain Health Intervention for Patients with Parkinson’s Disease and Mild Cognitive Impairment (PD-MCI)

G. Roth, D. Gonzalez (Chicago, USA)
Phosphorylated High Mobility Group Box Protein 2 (HMGB2) as a Potential Biomarker for Parkinson’s Disease

J. Fan, J. Liu, C. Mesaros, I. Blair (Philadelphia, USA)
Physical, Mental, and Socioemotional Functional Improvement Following Valbenazine Treatment for TD: a Case Series

R. Bera, J. Nedzesky, I. Gandayuwana, D. Winkelman, D. Vanderhoef, M. Bron, M M. Perez-Rodriguez (San Diego, USA)
Physician Assessment of Non-Medical Toxin Switching on Patient Care

P. Charles, L. Venditti, M. Nelson, R. Singh, K. Pazira, H. Kling, L. Kopaeva, S. Sharp, K. Harper (Nashville, USA)
Physiological assessment of swallowing related muscles in patients with Parkinson’s disease: characteristics and utility of high-density surface electromyography

M. Nakamori, K. Yoshikawa, Y. Nishikawa, M. Toko, H. Yamada, H. Maruyama (Hiroshima, Japan)
Physiotherapy for Dystonia in the UK: Current Practice, Patient Perspectives, and Future Directions

K. Sampson, I. Varela, H. Louissant, K. Holt, A. Batla, G. Nielsen, A. Sadnicka (London, United Kingdom)
Pilot Feasibility Data using Augmented Reality and Machine Learning-Based Digital Cognitive Assessment in Parkinson’s disease

K. Poplawska-Domaszewicz, A. Brek, K. Wu, N. Griffin, S. Fallone, M. Iulita, E. Streel, A. Kurta-Nowicka, K. Naskret-Gasik, J. Konczak, K. Ray Chaudhuri (Poznan, Poland)
Pilot Study: Shear Wave Elastography as a Potential Biomarker in Task-Specific Dystonia

A. Ly, A. Mushtaheed, A. Roberts, M. Druckenbrod, J. Stowers, M. Soliman, P. Lind, Y. Assefa, C. Stanley, A. Gravunder, J. Matsubara, C. Zampieri-Gallagher, D. Ehrlich, B. Karp, F. Gavelli, K. Alter (Bethesda, USA)
PINK1 activation improves outcomes in the UQCRC1 models of Parkinson’s disease

JL. Li, CC. Chan, CH. Lin (New Taipei City, Taiwan)
Planning for the Parkinson’s Pandemic: Care needs in Australian Residential Aged Care Facilities

J. Mcginley, S. Soh, Y. Mok, M. Callisaya, V. Mcconvey, M. Klaic, A. Vogel, D. Koye, D. Finkelstein, K. Bower (Parkville, Australia)
Plasma Biomarkers Predict Clinical Outcomes in Individuals with Neuronal α-Synuclein Disease and Amyloid-β Co-Pathology

S. Lorkiewicz, C. Abdelnour, A. Smith, N. Siddiqui, L. Montoliu-Gaya, E. Wilson, N. Ashton, B. Arslan, M. Plastini, C. Young, J. Winer, M. Shahid-Besanti, H. Vossler, V. Ramirez, G. Kerchner, K. Andreasson, V. Henderson, T. Montine, L. Tian, E. Mormino, H. Zetterberg, K. Poston (Gothenburg, Sweden)
Plasma Lipids as Potential Biomarkers for Progression of Sleep Disturbances in Parkinson’s Disease

M. Mchorney, R. Rajhmohan, J. Ruiz Tejeda, N. Phielipp (Irvine, USA)
Plasma Neurofilament Light Chain and Orthostatic Hypotension in Isolated REM Sleep Behavior Disorder: A Biomarker for α-Synucleinopathy Progression

A. Calculli, D. Di Martino, P. Grillo, G. Bellini, C. Fazio, D. Comolli, D. Hoxhaj, S. Cerri, M. Terzaghi, A. Pisani (Pavia, Italy)
Plasma neurofilament light chain in early Parkinson’ s disease predicts motor complications: A Prospective Cohort Study

NN. Che (Chengdu, Sichuan, China)
Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease

T. Tropea, P. Aldea Stevenson, M. Flitter, D. Meehan, A. Morris, M. Lu, L. Iaccarino, E. Collins, M. Hodsdon, L. Shaw, E. Lee, D. Weintraub, A. Chen-Plotkin, M. Mintun, A. Siderowf (Philadelphia, USA)
Plasma Protein Profiles Reveal Distinct Molecular Signatures in Parkinson’s Disease and Multiple System Atrophy

SJ. Chung, S. Jo, I. Jang, J. Lee, M. Choi, E. Lee (Seoul, Republic of Korea)
Plasma proteomic proﬁles and risk of Parkinson’s disease: a prospective study from UK Biobank

C. Li, B. Ke, X. Zheng, Y. Xiao, S. Wang, Q. Jiang, J. Lin, J. Huang, H. Shang (Chengdu, China)
Plasma tau-species-containing neuron-derived extracellular vesicles as potential biomarkers for progressive supranuclear palsy

YC. Zheng, HH. Cai, WY. Kou, ZW. Yu, T. Feng (Beijing, China)
Platelets Lipidome as Potential Biomarker of Parkinson’s Disease

G. Uras, S. Lucas-Del-Pozo, V. Lentini, F. Fierli, S. Koletsi, D. Hughes, A. Schapira, . (London, United Kingdom)
Pleozymes, A Multifunctional Nanozyme for Targeting Metabolic Deficits in Friedreich’s Ataxia

U. Khan, K. Mouli, A. Liopo, P. Derry, T. Kent (Houston, USA)
POLG2 Variant Reclassification Reveals Diagnosis in Adult with MSA-C Phenotype

M. Rochman, A. Dessy (Philadelphia, USA)
Pontine Hemorrhage leading to Bilateral Olivary Degeneration and Cervical Dystonia

M. Iqbal, C. Tarolli, D. Manou (Rochester, USA)
Poor sleep quality is one of the causes of cognitive decline in Parkinson’s disease (PD)-1

K. Hasegawa, M. Miyashita, M. Sagawa, A. Kawanami (Kanagawa, Japan)
Positive post-intervention effect of Biodanza therapy on inhibitory control related to the orbitomedial prefrontal cortex.

M. Moreno, M. Aveiga, J. Guapisaca, G. Bueno, M. Pinos (CUENCA, Ecuador)
Positive Relationship Between Improvement in Sleep and Quality of Life During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion

R. Hauser, A. Videnovic, P. Odin, K. Chaudhuri, M. Shah, J. Homola, L. Bergmann, R. Gupta, O. Vaou (Tampa, USA)
Post-stroke movement disorders following infarction of the basal ganglia: a pilot study.

L. Rigon, AT. Cimmino, D. Genovese, AR. Bentivoglio, C. Piano, P. Calabresi, G. Della Marca (Venice, Italy)
Poststroke Movement Disorders: An International Multicentre Study by the MDS Poststroke Movement Disorders Study Group

R. Mehanna, E. Ellis, K. Gulati, A. Mukherjee, A. Shalash, J. Jankovic, C. Falup-Pecurariu, A. Espay, L. Wang, J. Abanto, E. Dietrichs, S. Bjerknes, H. Holm, C. Armas, C. Cosentino, A. Wagle Shukla, J. Kungshamn, E. Myller, E. Ottela, H. Sarva, H. Ooi, G. Mostile, G. Lanza, M. Tripodi, R. Bella, F. Rodriguez-Porcel, S. Pandey, J. Joutsa (Houston, USA)
Potential Disease-Modifying Effects in Mild Parkinson’s Disease following High Intensity Aerobic Exercise: a Case Report

L. Goh, N. Allen, G. Angelis, S. Meikle, N. Johnson, J. Lv, C. Sue, S. Paul (Camperdown, Australia)
Precision Functional MRI Mapping of Therapeutic Response in Focal Hand Dystonia

A. Morris, L. Xavier, A. Meyer, E. Gordon, S. Norris (Saint Louis, USA)
Precision Gene Therapy Results in Clinical Benefit and Developmental Gains for Aromatic L-Amino Acid Decarboxylase Deficiency (AADCd): The UK Experience

A. Salazar-Villacorta, R. Spaull, L. Carr, J. Hassell, S. Pope, S. Heales, R. Shihurkar, K. Bankiewicz, T. Pearson, K. Aquilina, M. Kurian (London, United Kingdom)
Precision Management of Oromandibular Dystonia (OMD): The Role of Neurological examination, Electromyographic (EMG) Guidance, and Odontological evaluation (OE) – A descriptive study with a Multidisciplinary Approach for Botulinum Toxin A (BoNT/A) Treatment

A. Stark, H. Biernat, K. Benedek, P. Mcgettigan, M. Bakke, A. Lokkegaard (Rsokilde, Denmark)
Predicting Long Term Outcome of Gait Kinematics with Chronic Deep Brain Stimulation in Patients with Parkinson’s Disease

J. Al Ali, S. Miocinovic, L. Mckay, J. Nocera, F. Isbaine, J. Tran, P. Testini, S. Triche, C. Esper, P. Aia, L. Scorr, L. Higginbotham, R. Tripathi, N. Au Yong, C. Buetefisch (Atlanta, USA)
Predicting Parkinson’s Disease Motor Progression Using Clinical and Digital Data

T. Aubourg, K. Gunter, C. Lo, J. Welch, K. Groenewald, J. Klein, J. Razzaque, L. van Hillegondsberg, PL. Ratti, A. Nastasa, G. Auld, R. Mccomish, A. King, K. Chowdhury, N. Vijiaratnam, C. Girges, T. Foltynie, S. Arora, M. Hu (Sheffield, United Kingdom)
Predicting Parkinson’s disease severity and cognitive decline using blood-based ferroptotic biomarkers

V. Huin, E. Cailliau, G. Garçon, M. Dutheil, O. Simonin, N. Beauval, J. Labreuche, D. Blum, C. Moreau, E. Hainque, A. Marques, A. Eusebio, I. Benatru, C. Brefel-Courbon, D. Maltete, C. Giordana, M. Tir, S. Thobois, JP. Brandel, B. Jarraya, L. Hopes, O. Rascol, JC. Corvol, D. Devos, AS. Rolland (Lille, France)
Predicting the Cognitive-Psychiatric Phenotype of Parkinson’s Disease

H. Dhanis, J. Potheegadoo, S. Stampacchia, F. Bernasconi, C. Stucker, M. Maradan, L. Thanh, L. Jenni, J-A. Ghika, P. Burkhard, B. Vicki, D. Benninger, J. Horvath, P. Krack, D. de Ville, O. Blanke (Bern, Switzerland)
Predictive clinical factors for the faster progression from idiopathic late-onset cerebellar ataxia to multiple system atrophy cerebellar type

SM. Lee, HJ. Kim, JH. Shin (Seoul, Republic of Korea)
Predictor of post-deep brain stimulation cognitive decline in Parkinson’s disease patients

L. Montaser-Kouhsari, E. Narinsky, M. Fox (Boston, USA)
Predictors of Clinical Benefit from Adaptive DBS Compared to Conventional DBS in Parkinson’s Disease

J. Tanimura, T. Hashimoto (Matsumoto, Japan)
Predictors of Cognitive Impairments and Mood Disorders after Subthalamic Deep Brain Stimulation in Patients with Parkinson’s Disease

O. Alenikova, M. Dymkovskaya, A. Bunyak, E. Mykitchuk, S. Kantsevich (Minsk, Belarus)
Predictors of Health-Related Quality of Life in Parkinson’s Disease: A Five-Year Longitudinal Study

O. Zabala-Gómez, O. Lucas-Jiménez, B. Tijero, I. Gabilondo, J. Peña, N. Ojeda, L. Zubiaurre-Elorza, J. Diez-Huici, M. Acera, R. Del Pino, JC. Gómez-Esteban, N. Ibarretxe-Bilbao (Bilbao, Spain)
Predictors of suicidal ideation amongst people with parkinsonism in the PRIME-UK cross-sectional study

S. Haworth, A. Nodehi, Y. Ben-Shlomo, E. Henderson, E. Tenison (Bristol, United Kingdom)
Predictors of Рostural Instability and Gait Disturbances after STN-DBS in Parkinson’s Disease

O. Alenikova, A. Chumak, L. Parhach, N. Alenikov (Minsk, Belarus)
PREDIGT 2.0: A Self-Administered, Two-Step Screening Tool to Identify Individuals with Parkinson’s Disease

J. Li, K. Grimes, J. Saade, N. Mauri, J. Tomlinson, A. Frank, D. Manuel, B. Mollenhauer, M. Schlossmacher (Ottawa, Canada)
Preliminary Results From an Italian Multicentric Study on Inherited Synaptopathies Characterized by Movement Disorders and Epilepsy

L. Pollini, S. Galosi, F. Nardecchia, M. Mastrangelo, M. Bologna (Rome, Italy)
Preoperative Occipital Hypoperfusion Predicts Cognitive Decline after Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease

Y. Chishiki, S. Hirano, T. Yamamoto, Y. Nakano, M. Tamura, A. Sugiyama, T. Horikoshi, Y. Higuchi, S. Kuwabara (Chiba, Japan)
Preoperative Predictors of Post-DBS Cognitive Decline: Cardiac MIBG Imaging and Levodopa Burden as Risk Factors for Dementia in Parkinson’s Disease

DG. Park, YS. Kim, MS. Kim, JH. Yoon (Suwon, Republic of Korea)
Preservation of Putamen Volume with Aging in Cervical Dystonia, not other focal dystonia subtypes: A Cross-Sectional Neuroimaging Study

M. Owusu-Ansah, A. Tanenbaum, J. Hood, A. Eid, S. Grossen, A. Morris, PT. Kotzbauer, J. Perlmutter, MC. Campbell, SA. Norris (Saint Louis, USA)
Preserved neuroplasticity in patients affected by Parkinson’s disease responders to auditory cueing strategies

L. Avanzino, A. Botta, V. Romano, J. Nonnekes, M. Gilat, I. Maidan, E. Pelosin (Genoa, Italy)
Prevalence and Characteristics of Glucocerebrosidase Genetic Variants in Nepalese Early-onset Parkinson’s Disease Patients

R. Ojha, B. Gajurel, N. Gautam, R. Karn, R. Rajbhandari, S. Shahi, V. Sharma, S. Baidya, A. Bhattarai, A. Niraula, E. Tuladhar, A. Adhikari, Y. Tay, S. Lim, A. Tan (Kathmandu, Nepal)
Prevalence and Clinical Characteristics of iNPH-Related Imaging Findings (DESH) in Parkinson’s Disease

T. Baba, T. Totsune, T. Nakamura, Y. Sugimura, H. Oizumi, H. Tanaka, T. Takahashi, M. Yoshioka, K. Nagamatsu, T. Hasegawa, A. Takeda (Sendai, Japan)
Prevalence and Clinical Characteristics of Parkinson’s disease in Rural Nepal: A Community-Based Cross-Sectional Study

A. Chandra, A. Chandra, S. Acharya (Kathmandu, Nepal)
Prevalence and Comorbidities of Orthostatic Hypotension in Older Adults: A Two-Year Study

ANA. Ovchynnykova, Y. Trufanov (Kyiv, Ukraine)
Prevalence and Local Ancestry of LRRK2 p.Q1111H in Latin American Cohort

E. Waldo, TP. Leal, M. Inca-Martinez, S. Alcauter, G. Arboleda Bustos, C. Avila, V. Borges, P. Chana, M. Cornejo-Olivas, E. Gatto, G. Letro, B. Lobato, D. Martinez-Ramirez, A. Medina, V. Muller, P. Neto, K. Nuytemans, P. Olguin, J. Orozco Velez, V. Raggio, M. Rodriguez-Violante, A. Schuh, G. Torrealba, V. Tumas, C. Velez-Pardo, A. Viñuela, IF. Mata (Cleveland, USA)
Prevalence and Management of Depression Among Parkinson’s Patient’s in an Outpatient Clinic Setting

E. Parker, T. Siriwardena (Perth, Australia)
Prevalence of Central Pain in Parkinson’s Disease: A Systematic Review and Meta-analysis

K. Vieira, L. Pereira, G. Trevisan (Santa Maria, Brazil)
Prevalence of Essential Tremor in elderly people in Southern Brazil

C. Sangali, G. Pereira, D. Dos Santos, N. Bruscato, A. Schumacher Schuh, C. Rieder (Porto Alegre, Brazil)
Prevalence of Supine Hypertension in Alpha-Synucleinopathies: a Systematic Review and Meta-Analysis

V. Arca, PR. Lopes, FL. Westphal Filho, F. Mendes Filho, C. Falcão, J. Parmera (São Paulo, Brazil)
Prevalence of Transcobalamin Receptor Antibodies and Relationships with Vitamin B12 and Holotranscobalamin in Parkinson’s Disease

C. Christine, J. Pluvinage, P. Auinger, E. Forti, L. Tat, R. Green, M. Wilson (San Francisco, USA)
Prevalence of urinary problems in men and women with Parkinson’s disease. A study from the Mexican Parkinson’s Research Network.

A. Garcia, A. Fierro, A. Solari, P. Reyes, A. Lazaro, E. Morelos, C. Guerra, I. Estrada, K. Salinas, Y. Matuk, N. Gandarilla, U. Caballero, P. Montés, V. Flores, I. Espinosa, A. Hayas, E. Gaspar, D. Vazquez, M. Rodriguez, E. Waldo, T. Leal, M. Inca, I. Mata, S. Alcauter, M. Renteria, A. Medina, A. Ruiz (CDMX, Mexico)
Prevalence, demographic characteristics of Parkinson disease and associated comorbidities: An analysis of the Colombian Ministry of Health official registry

A. Rincon, C. Pantoja, J. Torres, C. Tamayo, D. Rosselli (Bogotá, Colombia)
Privacy and Personalisation: Predicting Parkinson’s Severity with Federated Learning

C. Hinchliffe, H. Hiden, E. Packer, P. Brown, A. Yarnell, L. Rochester, L. Alcock, M. Peeters, S. Del Din, P. Watson (Newcastle upon Tyne, United Kingdom)
Proactive Brain Health Alliance Serving Those at Risk for Neurodegenerative Disease

A. Mitchell, P. Mahant, S. Winter, K. Merkel (Phoenix, USA)
Probing Social Cognition and Emotional Facial Expression Recognition in Cervical Dystonia through Integration of EEG and Eye-Tracking

D. Diez Clarke, V. Georgiadou, C. O'Keeffe, J. Inocentes, A. Gallagher, S. Rafee, O. Killian, L. Williams, S. O'Riordan, M. Hutchinson, R. Reilly, C. Fearon (Dublin, Ireland)
Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson’s Disease – A Randomized, Placebo-Controlled Trial (Short Title: ProD)

A. Lemkow, A. Kuan, J. Lam, F. Vila-Rodriguez, M. Mckeown, J. Squires, A. Howard, S. Appel-Cresswell (Vancouver, Canada)
Prodromal Clinical Markers of Parkinson disease in patients with Gaucher disease and their parents

WZ. Hu, Q. Yang, Y. Huang (Guangzhou, China)
Prodromal Lewy body dementia features in isolated REM sleep behavior disorder with neuronal synuclein disease

D. Weintraub (Philadelphia, USA)
Prodromal Parkinson’s Disease in Agent Orange Exposed US Vietnam Veterans

E. Uc, C. Weber, M. Lenz, J. Dawson (Iowa City, USA)
Profile and Predictors of Depression in Parkinson’s Disease Patients attending the Neurology Clinic at the University College Hospital, Ibadan, Nigeria.

A. Fagbemi, F. Taiwo, T. Sodimu (East Midlands, United Kingdom)
Profiling Neural Protein Dopaminylation in Parkinson’s disease

W. Chen, I. Maze (NEW YORK, USA)
Programming Strategies to Improve Stimulation-Induced Dysgeusia: A Rare-Side Effect In Deep Brain Stimulation For Essential Tremor

Y. Degirmenci, A. Yilmaz (Istanbul, Turkey)
Progression of Motor & Non-motor symptoms of Parkinson’s Disease with Prior History of Head Trauma

C. Kastoun, R. Rajmohan, J. Ruiz Tejeda, N. Phielipp (Orange, USA)
Progressive Ataxia in a Young Patient: Atypical Presentation of a Probable Creutzfeldt-Jakob Disease Variant VV1

F. R. Rodrigues, D. S. Rocha, D. M. Natividade, J. D. Péres, D. Di Luca, L. B. Magalhães (Vicosa, Brazil)
Promising Remote Markers of Motor Progression in Isolated REM Sleep Behaviour Disorder

M. Patyjewicz, A. Zirra, B. Kansu, H. Chohan, L. Pérez-Carbonell, A. Noyce, C. Simonet (London, United Kingdom)
Proof-of-Concept Study Design Leveraging Digital Biomarkers to Enhance Statistical Power and Reduce Sample Size in PD Trials

S. Hendrix, J. Christensen, S. Jackson, P. O'Keefe, K. Hendrix, S. Dheerendra, F. Nahab, S. Dickson (Millcreek, USA)
Prospective observational study on the effects of physical exercise and lifestyle modifications in patients with Parkinson’s disease

T. Lata (Mumbai, India)
Prospective Tractography-Guided STN DBS Targeting with Optimized vmPFC Connectivity for Apathy in PD a Case Report

J. de Bruin, K S. Choi, J. Jimenez-Shahed, B. Kopell, H. Mayberg, M. Figee (New York, USA)
Protective effects of Hesperidin loaded polymeric nanoparticles on the progression of MPTP Induced Parkinson’s disease via targeting GPR43/NLRP3 signaling pathway: in vitro and in vivo studies

M. Singh (Prayagraj, India)
Proteome-Wide Association Study Identifies Plasma β-Glucuronidase as a Causal Risk Protein for Multiple System Atrophy

X. Chen, X. Wang, B. Wang, W. Luo (Hangzhou, China)
Proteomic analysis identifies GGA1, SCP2, and RABEPK as risk protein of multiple system atrophy

B. Ke, C. Li, X. Zheng, Y. Xiao, S. Wang, Q. Jiang, J. Lin, J. Huang, H. Shang (Chengdu, China)
Psychometric Properties of the SCOPA-Cog Turkish version

S. Isazade, H. Ozden, D. Gunal (Istanbul, Turkey)